Top

Published in:

01-03-2019 | Original Contributions

Impact of Bariatric Surgery on the Pharmacokinetics Parameters of Amoxicillin

Authors: Marina Becker Sales Rocha, Gilberto De Nucci, Francisco Ney Lemos, Rodrigo Feitosa de Albuquerque Lima Babadopulos, Andrea Vieira Pontes Rohleder, Francisco Vagnaldo Fechine, Natalícia J. Antunes, Gustavo D. Mendes, Demetrius Fernandes do Nascimento, Manoel Odorico de Moraes, Maria Elisabete Amaral de Moraes

Published in: Obesity Surgery | Issue 3/2019

Abstract

Background

Bariatric surgery leads to several anatomo-physiological modifications that may affect pharmacokinetic parameters and consequently alter the therapeutic effect of drugs, such as antibiotics. The pharmacokinetics of oral amoxicillin after Roux-en-Y gastric bypass (RYGB) surgery is unknown.

Objectives

The objective of this study was to evaluate the impact of bariatric surgery on the pharmacokinetics of amoxicillin.

Methods

This study was performed as a randomized, open-label, single-dose clinical trial, with two periods of treatment, in which obese subjects (n = 8) received an amoxicillin 500 mg capsule orally before and 2 months after the RYGB surgery. The amoxicillin plasma concentration was determined by liquid chromatography coupled to mass spectrometry (LC-MS/MS).

Results

After the surgery, the mean weight loss was 17.03 ± 5.51 kg, and mean body mass index (BMI) decreased from 46.21 ± 2.82 to 38.82 ± 3.32 kg/m². The mean amoxicillin area under the plasma concentration versus time curve from time zero to the time of the last quantifiable concentration (AUC_0–tlast) increased significantly (3.5-fold); the maximum plasma concentration (C_max) increased 2.8-fold after the bariatric surgery. No correlation was found between amoxicillin absorption, BMI, and weight loss percentage.

Conclusion

The alterations observed in the amoxicillin pharmacokinetics suggest that obese subjects included in this trial had a substantially increase in amoxicillin systemic exposure after RYGB surgery. However, despite this increase, its exposure was lower than the values reported for non-obese volunteers.

Trial Registration

Identifiers: NCT03588273

Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann. Pharmacother. 2012;46(1):130–6. Available from: http://journals.sagepub.com/doi/10.1345/aph.1Q414 CrossRefPubMed

Ontario HQ. Bariatric surgery: an evidence-based analysis. Ont. Health Technol. Assess. Ser. 2005;5(1):1–148. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382415/

Wang Y, Zhang C. Bariatric surgery to correct morbid obesity also ameliorates atherosclerosis in patients with type 2 diabetes mellitus. Am. J. Biomed. Sci. 2009;1(1):56–69. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776741/ CrossRefPubMedPubMedCentral

Brocks DR, Ben-Eltriki M, Gabr RQ, et al. The effects of gastric bypass surgery on drug absorption and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 2012;8(12):1505–19. Available from. https://doi.org/10.1517/17425255.2012.722757.CrossRefPubMed

Pei Q, Yang G-P, Li Z-J, et al. Simultaneous analysis of amoxicillin and sulbactam in human plasma by HPLC-DAD for assessment of bioequivalence. J Chromatogr B. 2011;879(21):2000–4. Available from: http://www.sciencedirect.com/science/article/pii/S1570023211003266 CrossRef

Liew KB, Loh GO, Tan YT, et al. Randomized two-way cross-over bioequivalence study of two amoxicillin formulations and inter-ethnicity pharmacokinetic variation in healthy Malay volunteers. Biomed. Chromatogr. 2014;28(9):1246–53. Available from. https://doi.org/10.1002/bmc.3153.CrossRefPubMed

European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe 2012. Stockholm: 2014. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-consumption-europe-esac-net-2012.pdf.

de Velde F, consortium on behalf of the C-N, de Winter BCM, et al. Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. J. Antimicrob. Chemother. 2016;71(10):2909–17. Available from. https://doi.org/10.1093/jac/dkw226.CrossRefPubMed

Dollery C. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1998.

10.

Mouton JW, Brown DFJ, Apfalter P, et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin. Microbiol. Infect. 2012;18(3):E37–45. Available from. https://doi.org/10.1111/j.1469-0691.2011.03752.x.CrossRefPubMed

11.

Paintaud G, Alván G, Dahl ML, et al. Nonlinearity of amoxicillin absorption kinetics in human. Eur J Clin Pharmacol. 1992;43(3):283–8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/1425893 CrossRefPubMed

12.

Barr WH, Zola EM, Candler EL, et al. Differential absorption of amoxicillin from the human small and large intestine. Clin Pharmacol Ther. 1994;56(3):279–85. Available from. https://doi.org/10.1038/clpt.1994.138.CrossRefPubMed

13.

Schramm SG. Use of meta-analysis to evaluate the interchangeability of medicines [in Portuguese; habilitation thesis]. São Paulo (BR): University of São Paulo, 2008.

14.

Lacy CF, Armstrong LL, Goldman MP, et al. Drug information handbook: a comprehensive resource for all clinicians and healthcare professionals. 17th ed. Lexi-Comp: American Pharmacists Association. Ed; 2008-2009.

15.

Arancibia A, Guttmann J, González G, et al. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob. Agents Chemother. 1980;17(2):199–202. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC283758/ CrossRefPubMedPubMedCentral

16.

Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am. J. Heal. Pharm. 2006;63(19):1852–7. Available from: http://www.ajhp.org/content/63/19/1852.long?sso-checked=true CrossRef

17.

Oliveira CH, Abib E, Vannuchi YB, et al. Comparative bioavailability of 4 amoxicillin formulations in healthy human volunteers after single dose administration. Int J Clin Pharmacol Ther. 2001;39(4):167–72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11332873 CrossRefPubMed

18.

Guidance for industry bioanalytical method validatione, 2001. Available from: https://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf.

19.

Agência Nacional de Vigilância Sanitária, 2003. Available from: http://www.anvisa.gov.br/hotsite/genericos/legis/resolucoes/2003/899_03re_e.pdf.

20.

Hamilton R, Thai XC, Ameri D, et al. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J. Antimicrob. Chemother. 2013;68(3):666–73. Available from. https://doi.org/10.1093/jac/dks431.CrossRefPubMed

21.

Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol. Drug Saf. 2013;22(9):970–6. Available from. https://doi.org/10.1002/pds.3461.CrossRefPubMed

22.

Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J. Am. Soc. Nephrol. 2003;14(6):1480–6. Available from: http://jasn.asnjournals.org/content/14/6/1480.abstract CrossRefPubMed

23.

Skottheim IB, Stormark K, Christensen H, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin. Pharmacol. Ther. 2009;86(3):311–8. Available from. https://doi.org/10.1038/clpt.2009.82.CrossRefPubMed

24.

De Smet J, Colin P, De Paepe P, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J. Antimicrob. Chemother. 2012;67(1):226–9. Available from. https://doi.org/10.1093/jac/dkr436.CrossRefPubMed

25.

Navarro-Díaz M, Serra A, Romero R, et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J. Am. Soc. Nephrol. 2006;17(12 suppl 3):S213–7. Available from: http://jasn.asnjournals.org/content/17/12_suppl_3/S213.abstract CrossRefPubMed

Title: Impact of Bariatric Surgery on the Pharmacokinetics Parameters of Amoxicillin
Authors: Marina Becker Sales Rocha
Gilberto De Nucci
Francisco Ney Lemos
Rodrigo Feitosa de Albuquerque Lima Babadopulos
Andrea Vieira Pontes Rohleder
Francisco Vagnaldo Fechine
Natalícia J. Antunes
Gustavo D. Mendes
Demetrius Fernandes do Nascimento
Manoel Odorico de Moraes
Maria Elisabete Amaral de Moraes
Publication date: 01-03-2019
Publisher: Springer US
Published in: Obesity Surgery / Issue 3/2019
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-018-3591-3

At a glance: The STEP trials

Springer Medicine

Impact of Bariatric Surgery on the Pharmacokinetics Parameters of Amoxicillin

Abstract

Background

Objectives

Methods

Results

Conclusion

Trial Registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusion

Trial Registration

Please log in to get access to this content

Other articles of this Issue 3/2019

Revision of Roux-en-Y Gastric Bypass with Limb Distalization for Inadequate Weight Loss or Weight Regain

Prospective Assessment of Postoperative Nausea Early After Bariatric Surgery

Systematization of Nutritional Care In Endoscopic Treatment for Obesity

Response to Letter to the Editor Re: “EUS-Guided Intragastric Injection of Botulinum Toxin A in the Preoperative Treatment of Super-Obese Patients: a Randomized Clinical Trial”

Incidence of Diabetes Mellitus, Cardiovascular Diseases, and Cancer in Patients Undergoing Malabsorptive Surgery (Biliopancreatic Diversion and Biliointestinal Bypass) vs Medical Treatment

Esophageal Squamous Cell Carcinoma After Adjustable Gastric Banding